Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 2,963 · FY2023 2,749 · FY2024 3,804 — 3-yr total 9,516
Ivermedi (შპს ივერმედი) — wholesaler of pharmaceutical and medical goods. RMS NACE declaration 46460 (wholesale of pharmaceutical goods); bia.ge lists various medical equipment and products; gross margin ~22% on GEL 46m of FY2024 revenue, a distribution profile. An earlier description called it a private medical clinic; no filing or directory record supports that.
Group parent — controls 1 company · ownership
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 28.3% | 25.8% | 24.8% | 22.8% | 21.1% | 20.7% | 23.4% | 21.9% |
| EBITDA Margin | 10.9% | 8.1% | 8.2% | 8.3% | 7.5% | 1.0% | 6.6% | -2.4% |
| EBITDAR | 4,181 | 3,055 | 3,550 | 3,304 | 3,488 | 386 | 3,129 | -1,095 |
| EBITDAR Margin | 10.9% | 8.1% | 8.2% | 8.3% | 7.5% | 1.0% | 6.6% | -2.4% |
| EBIT Margin | 10.9% | 8.1% | 8.2% | 8.3% | 7.5% | 1.0% | 6.6% | -2.4% |
| Net Profit Margin | 11.4% | 8.0% | 9.4% | 14.0% | 14.2% | 1.2% | 9.3% | -2.2% |
| Operating Expense % of Sales | 17.4% | 17.7% | 16.5% | 14.5% | 13.7% | 19.7% | 16.8% | 24.3% |
| Returns | ||||||||
| Return on Assets (ROA) | 11.9% | 8.4% | 10.3% | 12.0% | 15.3% | 1.2% | 10.3% | -2.6% |
| Return on Equity (ROE) | 16.2% | 10.7% | 12.8% | 15.8% | 18.2% | 1.4% | 12.3% | -3.2% |
| ROIC [EBIT / Invested Capital] | 17.7% | 14.0% | 14.4% | 12.2% | 14.0% | 1.7% | 11.9% | -5.0% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 8.9% | 6.1% | 2.8% | 0.1% | 0.1% | 0.1% | 0.1% | 1.5% |
| Debt-to-Equity | 0.12x | 0.08x | 0.04x | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x |
| Debt-to-EBITDA | 0.78x | 0.71x | 0.31x | 0.01x | 0.01x | 0.10x | 0.01x | N/A |
| Equity-to-Assets | 73.3% | 78.8% | 80.0% | 75.8% | 84.1% | 84.2% | 84.1% | 79.3% |
| Net Debt | -3,266 | -6,441 | -6,914 | -8,242 | -11,626 | -10,924 | -9,424 | -9,078 |
| Cash & Equivalents | 6,525 | 8,625 | 8,025 | 8,279 | 11,666 | 10,964 | 9,464 | 9,676 |
| Total Debt | 3,259 | 2,184 | 1,111 | 37 | 40 | 40 | 40 | 598 |
| Liquidity & working capital | ||||||||
| Current Ratio | 2.90x | 3.37x | 3.19x | 2.83x | 4.46x | 4.21x | 4.07x | 3.08x |
| Quick Ratio | 2.05x | 2.66x | 2.66x | 1.97x | 3.52x | 3.66x | 3.61x | 2.32x |
| Cash Ratio | 0.86x | 1.33x | 1.02x | 0.74x | 1.70x | 1.73x | 1.41x | 1.28x |
| Total Current Assets | 22,095 | 21,872 | 25,140 | 31,758 | 30,671 | 26,617 | 27,245 | 23,327 |
| Total Current Liabilities | 7,619 | 6,496 | 7,883 | 11,212 | 6,879 | 6,324 | 6,700 | 7,571 |
| Inventory | 6,499 | 4,567 | 4,205 | 9,680 | 6,428 | 3,443 | 3,078 | 5,779 |
| Trade Receivables | 8,168 | 8,016 | 12,019 | 12,778 | 12,037 | 11,194 | 13,381 | 5,888 |
| Trade Payables | 6,431 | 5,352 | 6,745 | 11,155 | 6,822 | 6,104 | 6,700 | 7,247 |
| Net Working Capital | 14,476 | 15,376 | 17,257 | 20,546 | 23,792 | 20,293 | 20,545 | 15,756 |
| Net Working Capital % of Revenue | 37.8% | 40.7% | 40.1% | 51.6% | 50.8% | 52.6% | 43.6% | 34.3% |
| Trade Working Capital | 8,236 | 7,231 | 9,479 | 11,303 | 11,643 | 8,533 | 9,759 | 4,420 |
| Trade Working Capital % of Revenue | 21.5% | 19.1% | 22.0% | 28.4% | 24.9% | 22.1% | 20.7% | 9.6% |
| Change in Trade Working Capital | N/A | -1,005 | 2,248 | 1,824 | 340 | -3,110 | 1,226 | -5,339 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | 4.22x | 6.14x | 7.70x | 3.17x | 5.74x | 8.87x | 11.73x | 6.21x |
| Days Inventory Outstanding (DIO) | 86.5 | 59.4 | 47.4 | 115.1 | 63.6 | 41.1 | 31.1 | 58.8 |
| Receivables Turnover | 4.69x | 4.72x | 3.58x | 3.11x | 3.89x | 3.44x | 3.52x | 7.80x |
| Days Sales Outstanding (DSO) | 77.9 | 77.4 | 101.9 | 117.2 | 93.9 | 106.0 | 103.6 | 46.8 |
| Payables Turnover | 4.27x | 5.24x | 4.80x | 2.75x | 5.41x | 5.01x | 5.39x | 4.95x |
| Days Payable Outstanding (DPO) | 85.6 | 69.6 | 76.0 | 132.6 | 67.5 | 72.9 | 67.8 | 73.7 |
| Cash Conversion Cycle | 78.8 days | 67.2 days | 73.3 days | 99.7 days | 90.0 days | 74.2 days | 67.0 days | 31.8 days |
| Asset Turnover | 1.04x | 1.06x | 1.09x | 0.86x | 1.08x | 0.95x | 1.11x | 1.18x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 5,787 | 5,777 | 2,871 | 3,283 | 6,208 | 3,833 | 1,837 | 4,431 |
| Free Cash Flow (OCF − Capex proxy) | 5,787 | 5,513 | 2,693 | 2,303 | 9,358 | 3,408 | 954 | 3,318 |
| Cash Conversion (OCF / EBITDA) | 138.4% | 189.1% | 80.9% | 99.4% | 178.0% | 993.0% | 58.7% | N/A |
| Dividends Declared | 1,647 | 2,306 | 2,315 | 1,916 | 5,440 | 2,963 | 2,749 | 3,804 |
| Dividend Payout Ratio | 37.8% | 76.5% | 57.0% | 34.4% | 81.7% | 621.2% | 62.7% | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →